期刊文献+

秋水仙碱对高脂血症新西兰兔血浆CRP和一氧化氮水平的影响

Effects of Colchicine therapy on plasma level of CRP and nitric oxide in New Zealand rabbits with hyperlipidemia
下载PDF
导出
摘要 目的探讨秋水仙碱对高脂血症新西兰兔血浆CRP和一氧化氮水平的影响。方法通过给予高脂饮食构建新西兰兔高脂血症模型,模型构建成功后干预组给予0.01 mg/kg秋水仙碱治疗,共2周。评估空白组、高脂血症对照组和高脂血症干预组3组新西兰兔血脂、CRP及一氧化氮水平。结果经8周高脂饮食饲养后,与空白组相比,高脂血症组新西兰兔血脂指标水平均明显升高,差异有统计学意义(均P<0.05);与空白组相比,血浆CRP水平在高脂血症组也明显升高,而一氧化氮水平则明显降低(P<0.05)。高脂血症干预组与高脂血症对照组血脂水平无明显差异,但高脂血症干预组血浆CRP水平明显降低,而一氧化氮水平则明显升高,与高脂血症对照组比较差异有统计学意义(均P<0.05)。结论秋水仙碱能够通过下调血浆CRP水平从而改善高脂血症新西兰兔血管内皮细胞功能,这可能是秋水仙碱能够减少冠心病患者心血管事件的其中一个作用机制。 Objective To investigate the effects of Colchicine therapy on plasma level of CRP and (nitric oxide) NO in New Zealand rabbits with hyperlipidemia. Methods Hyperlipidemia model was induced by institution of high cholesterol diet in New Zealand rabbits,and colchicines (0.01 mg/kg body weight)was administered for 2 weeks when hyperlipidemia model was established. Plasma level of lipid profile,CRP and NO were evaluated in blank group,hyperlipidemia control group and hyperlipidemia intervention group. Re-sults With 8 weeks high cholesterol diet treatment,plasma level of lipid profile was significantly higher when compared to blank group;and the plasma level of CRP was also higher while NO was lower in hyperlipidemia groups. There was no significant difference of lipid profile in hyperlipidemia control group and hyperlipidemia intervention group after 2 weeks colchicine therapy,however the plasma level of CRP was significant lower while NO was significant higher in the hyperlipidemia intervention group when compared to the hyperlipidemia control group. Conclusion Endothelial functions was improved by colchicine therapy in hyperlipidemia rab-bit,which may be ascribed to the down-regulation of CRP,and this may be one of the potential mechanisms colchicine reduce cardiovascular events in patients with coronary artery diseases.
出处 《新医学》 2013年第12期821-823,共3页 Journal of New Medicine
关键词 高脂血症 秋水仙碱 C-反应蛋白 一氧化氮 Hyperlipidemia Colchicine C-reactive protein Nitric oxide
  • 相关文献

参考文献13

  • 1蔡安平,麦炜颐.他汀类药物的多效性及其改善干细胞治疗心肌梗死疗效的潜能[J].新医学,2010,41(4):278-280. 被引量:8
  • 2Sherwood A, Blmnenthal JA, Hinderliter AL, et al. Worsening depressive symptoms are associated with ad- verse clinical outcomes inpatients with heart failure. JAm Coil Cardiol, 2011, 57: 418-423.
  • 3Weis M, Heeschen C, Glassford A J, et aL Statins have biphasic effects on angiogenesis. Circulation, 2002, 105 : 739-745.
  • 4Gargalovic PS, Imura M, Zhang B, et al. Identification of inflammatory gene modules based on variations of hu- man endothelial cell responses to oxidized lipids. Proc Natl Acad Sci U S A, 2006, 103: 12741-12746.
  • 5Nidorf SM, Eikelboom JW, Budgeon CA, et al. Low- dose colchicine for secondary prevention of cardiovascu- lar disease. J Am Coil Cardiol, 2013, 61 : 404-410.
  • 6Ridker PM, Danielson E, Fonseca FA, et al. Rosuvas- tatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med, 2008, 359 : 2195-207.
  • 7Elkind MS, Tai W, Coates K, et al. High-sensitivity C- reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke. Arch Intern Med, 2006, 166: 2073-2080.
  • 8Robins SJ, Collins D, Nelson J J, et al. Cardiovascular events with increased lipoprotein-associated phospho- lipase A (2) and low high-density lipoprotein-cholester- o1: the Veterans Affairs HDL Intervention Trial. Arterio- scler Tbrornb Vasc Biol, 2008, 28 : 1172-1178.
  • 9Cannon CP, Braunwald E, McCabe CH, et al. Inten- sive versus moderate lipid lowering with statins after a- cute coronary syndromes. N Engl J Med, 2004, 350: 1495-1504.
  • 10Yusuf S, Sleight P, Pogue J, et aL Effects of an angio- tensin-converting-enzyme inhibitor, ramipril, on cardio- vascular events in high-risk patients. The Heart Out- comes Prevention Evaluation Study Investigators. N Engl J Med, 2000, 342: 145-153.

二级参考文献20

  • 1OKURA H,MATSUYAMA A,LEE C M,et al.Cardiomyoblast-like cells differentiated from human adipose tissue-derived mesenchymal stem cells improve left ventricular dysfunction and survival in a rat myocardial infarction model[J].Tissue Eng Part C Methods,2009,[Epub ahead of print].
  • 2SHI R Z,LI Q P.Improving outcome of transplanted mesenchymal stem cells for ischemic heart disease[J].Biochem Biophys Res Commun,2008,376(2):247-250.
  • 3DAVIGNON J.Beneficial cardiovascular pleiotropic effects of statins[J].Circulation,2004,109(23 Suppl 1):III39-III43.
  • 4ETO M,L(U)SCHER T F.The cardioprotective effects of statins[J].Coron Artery Dis,2004,15(5):243-245.
  • 5MUNK P S,LARSEN A I.Inflammation and C-reactive protein in cardiovascular disease[J].Tidsskr Nor Laegeforen,2009,129(12):1221-1224.
  • 6BLUM A,SHAMBUREK R.The pleiotropic effects of statins on endothelial function,vascular inflammation,immunomodulation and thrombogenesis[J].Atherosclerosis,2009,203(2):325-330.
  • 7RIDKER P M,SILVERTOWN J D.Inflammation,C-reactive protein,and atherothrombosis[J].J Periodontol,2008,79(8 Suppl):1544-1551.
  • 8GELOSA P,CIMINO M,PIGNIERI A,et al.The role of HMG-CoA reductase inhibition in endothelial dysfunction and inflammation[J].Vasc Health Risk Manag,2007,3(5):567-577.
  • 9MATSUNO H,TAKEI M,HAYASHI H,et al.Simvastatin enhances the regeneration of endothelial cells via VEGF secretion in injured arteries[J].J Cardiovasc Pharmacol,2004,43(3):333-340.
  • 10BHATT D L.Anti-inflammatory agents and antioxidants as a possible "third great wave"in cardiovascular secondary prevention[J].Am J Cardiol,2008,101(10A):4D-13D.

共引文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部